The US Food and Drug Administration has awarded a rare paediatric disease designation to a subsidiary of Nippon Shinyaku Co Ltd for an experimental treatment for Duchenne muscular dystrophy (DMD). DMD is a genetic disease that causes progressive weakness and the loss of skeletal, cardiac and respiratory muscles. It occurs primarily in males.
